Treatment options (Box 8)

1) JointHealth™ Medications Guide

https://jointhealth.org/pdfs/MedicationsGuideJune2017.pdf

2) Arthritis Consumer Experts: JointHealth™ Education online course: JHEd:Advanced Therapies

http://info.jointhealth.org/jhed-landing-page

3) Arthritis Consumer Experts: Biosim•Exchange

https://biosim.jointhealth.org

4) Arthritis Consumer Experts: Biosimilars Education Videos

http://info.jointhealth.org/resources

5) EULAR: Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

https://ard.bmj.com/content/76/6/960

6) ACR: 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of Disease-Modifying Anti-Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis (RA)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081542/
RA Models of Care Toolkit
Medical management

7) EULAR: “Low-dose glucocorticoids are safe to use in early rheumatoid arthritis”

https://promotions.bmj.com/ardsummaries/2017/11/21/low-dose-glucocorticoids-are-safe-to-use-in-early-rheumatoid-arthritis/#more-698

8) EULAR: “Managing the use of glucocorticoid therapy in rheumatic disease”

https://promotions.bmj.com/ardsummaries/2016/08/18/managing-the-use-of-glucocorticoid-therapy-in-rheumatic-disease/

9) EULAR: “Biologics should be compared to the highest possible dose of methotrexate”

https://promotions.bmj.com/ardsummaries/2016/09/06/biologics-should-be-compared-to-the-highest-possible-dose-of-methotrexate/

10) EULAR: “Newly updated advice on using DMARDs for RA”

https://promotions.bmj.com/ardsummaries/2014/04/25/newly-updated-advice-on-using-dmards-for-ra/#more-23

11) EULAR: “Recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis”

https://ard.bmj.com/content/72/6/804


13) European Medicines Agency and European Commission: “Biosimilars medicines animated video for patients”

https://www.youtube.com/playlist?list=PL7K5dNgKnawb3lQri7IIr5wbaWxP71jQJ

14) European Commission: “Biosimilars information guide for patients”

http://ec.europa.eu/docsroom/documents/26643

15) “Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508389/

16) “Inequities in access to biologic and synthetic DMARDs across 46 European countries”

https://ard.bmj.com/content/73/1/198